The Efficacy and Safety of Intra-oral Topical Ketoprofen for the Treatment of Acute Migraine

NCT ID: NCT01228552

Last Updated: 2011-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of intra-oral topical ketoprofen for the treatment of acute migraine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Disorders Migraine Headache Migraine Acute Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Topical, intra-oral ketoprofen gel

Group Type ACTIVE_COMPARATOR

Topical, intra-oral ketoprofen gel

Intervention Type DRUG

Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Placebo gel

Group Type PLACEBO_COMPARATOR

Placebo gel

Intervention Type OTHER

Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topical, intra-oral ketoprofen gel

Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Intervention Type DRUG

Placebo gel

Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Established diagnosis of Migraine as per IHS with aura
* Established diagnosis of Migraine as per IHS without aura
* At least 2 migraines per month
* At least 18 years of age

Exclusion Criteria

* Pregnancy or Lactation
* Other Headache Conditions including basilar, hemiplegic, or ophthalmoplegic migraines
* Chronic Daily Headache
* Allergy or Sensitivity to NSAIDs
* Other Severe Medical Conditions including GI bleeding, blood dyscrasias, thrombocytopenia
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Behar, Caren, M.D.

INDIV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

New York Medical College

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Caren Behar, MD

Role: PRINCIPAL_INVESTIGATOR

New York Medical College

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York Medical College

Valhalla, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Caren Behar, MD

Role: CONTACT

914-584-2413

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

79,629

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ketone for Migraine Prevention
NCT05085483 COMPLETED NA